The EED Knockout HeLa Polyclonal Cells product is a heterogeneous population of HeLa cells engineered by CRISPR/Cas9-mediated gene disruption to eliminate EED function. As a polyclonal knockout, it avoids clonal biases and preserves genetic diversity, making it ideal for studying phenotypic variation. This loss-of-function model abolishes the scaffold role of EED in the Polycomb Repressive Complex 2 (PRC2), providing a robust system for epigenetic research.
HeLa is a well-established immortalized human cervical adenocarcinoma epithelial cell line with integrated HPV-18. It is extensively used in cancer biology for its robust proliferation, ease of transfection, and well-characterized epigenomic landscape. Its transformed phenotype and epithelial origin make it a relevant model for studying molecular mechanisms in cervical and other epithelial cancers. The HeLa background offers a highly tractable system to interrogate the consequences of EED ablation in a cancer context.
EED encodes a core scaffold protein of the PRC2 complex, which also consists of the methyltransferase EZH2, SUZ12, and RBBP4. EED binds trimethylated lysine 27 of histone H3 (H3K27me3) and allosterically stimulates EZH2 catalytic activity, thereby spreading this repressive chromatin modification. PRC2-mediated H3K27me3 leads to chromatin compaction and transcriptional silencing of critical target genes, including the HOX gene clusters and the tumor suppressor CDKN2A. EED activity is modulated by recruitment factors JARID2, AEBP2, and long non-coding RNAs such as HOTAIR, which direct PRC2 to specific genomic loci. Disruption of EED prevents PRC2 assembly and activity, resulting in global loss of H3K27me3, derepression of downstream genes, and pronounced effects on cell fate determination, proliferation, and differentiation. Thus, EED knockout provides a powerful tool to dissect PRC2-dependent gene silencing and its role in development and disease.
Within the HeLa cancer environment, loss of EED disrupts the epigenetic balance, potentially reactivating tumor suppressor genes and altering oncogenic programs. This model enables the study of PRC2 dysfunction in tumorigenesis and the evaluation of EZH2 inhibitors, which rely on a functional PRC2 complex. The polyclonal nature captures heterogeneous cellular responses, mimicking intratumoral diversity and providing a physiologically relevant platform for drug testing.
This product is ideal for a wide range of epigenetic and cancer research applications. It is particularly valuable for validating PRC2-targeted therapies, as EED knockout cells serve as essential controls for assessing drug specificity. Representative assays include Western blotting for H3K27me3 and PRC2 components, RT-qPCR and RNA-seq for transcriptome profiling, ChIP-qPCR for histone modifications, and functional assays such as proliferation, colony formation, and xenograft tumor models. For additional details, please contact Ascent Research.
